Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
about
The role of general nuclear medicine in breast cancerNoninvasive imaging of cardiovascular injury related to the treatment of cancerCardiac risk in the treatment of breast cancer: assessment and management.Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist.Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.An update on cardio-oncology.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and TrastuzumabCardiac side effects of anticancer treatments: new mechanistic insightsDoes diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Cardiotoxicity due to chemotherapy: role of cardiac imaging.Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
P2860
Q26801069-B05F86E9-FFAF-4886-8699-50BC907E8462Q27024715-E5D3F88C-9C66-4D94-B498-888B069DDC0EQ28081385-8D8D087A-7239-48B0-82E8-A2FF68A2EE40Q33741091-B0246BFD-995F-43F4-9FC6-CAAE7D7DFDB4Q33831903-4A628591-100C-42E8-B880-807C1F1777C8Q33949465-5809D359-F357-42AF-82E4-823A863C9CF2Q34650059-B4057E40-5E2B-4712-83FA-1A8E4A4E72D0Q35880224-E0C7CAC1-EC9E-4F4E-85EB-3A017981EEB9Q36064820-F32E1032-DDE0-4A72-B2D3-CBFB456516C9Q36957758-7F7B363B-473B-4222-9AE5-F8EF017CD2D3Q37116520-88500ECB-230F-4EA9-BED1-536F6CB3F6B1Q37158620-99340597-EB2E-4208-8EE3-7994A4C2A6CDQ37311943-925EAD04-6395-4EEF-9BDB-085579A7EA1EQ38343043-D63212EF-2DFA-41FB-A6A6-76666CCB1463Q39178080-9681BE6D-D004-4E00-8DD2-2C112A6CBC9FQ42706225-DA760C02-0196-4AEA-B3B5-42BFAB64ABCCQ49961375-6F59C144-F6F7-44BD-9CB0-D5260828C1DEQ54192533-7A208477-F14C-4101-ABDD-848C4CF37876
P2860
Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Baseline diastolic dysfunction ...... line therapy in breast cancer.
@en
Baseline diastolic dysfunction ...... line therapy in breast cancer.
@nl
type
label
Baseline diastolic dysfunction ...... line therapy in breast cancer.
@en
Baseline diastolic dysfunction ...... line therapy in breast cancer.
@nl
prefLabel
Baseline diastolic dysfunction ...... line therapy in breast cancer.
@en
Baseline diastolic dysfunction ...... line therapy in breast cancer.
@nl
P2093
P2860
P1476
Baseline diastolic dysfunction ...... line therapy in breast cancer.
@en
P2093
Alexandre Cochet
Alina Berriolo-Riedinger
Claude Touzery
François Brunotte
Gaetan Quilichini
Inna Dygai-Cochet
Michel Toubeau
Pierre Fumoleau
P2860
P2888
P304
P356
10.1007/S10549-011-1714-9
P407
P577
2011-09-15T00:00:00Z